Results 1 to 10 of about 32,046 (240)
Amyloidogenicity assessment of transthyretin gene variants [PDF]
Annals of Clinical and Translational Neurology, 2022 Objective Hereditary transthyretin‐mediated amyloidosis is a treatable condition caused by amyloidogenic variants in the transthyretin‐gene resulting in severe peripheral neuropathy or cardiomyopathy.
Nicolai B. Grether +11 more
doaj +2 more sources
Comparative Stability and Clearance of [Met30]Transthyretin and [Met119]Transthyretin [PDF]
FEBS Journal, 1997 [Met119]Transthyretin has been described as a non‐amyloidogenic transthyretin variant. In Portugal, it has also been found in compound heterozygotic individual carriers of [Met30]transthyretin, the most prevalent variant associated with familial amyloidotic polyneuropathy.
Maria João Saraiva, M T Hays
exaly +3 more sources
Evolution of Transthyretin in Marsupials [PDF]
European Journal of Biochemistry, 1995 The evolution of the expression and the structure of the gene for transthyretin, a thyroxine‐binding plasma protein formerly called prealbumin, was studied in three marsupial species: the South American polyprotodont Monodelphis domestica, the Australian polyprotodont Sminthopsis macroura and the Australian diprotodont Petaurus breviceps.
Duan W. +11 more
core +7 more sources
Cardiac Transthyretin Amyloidosis: Hidden in Plain Sight
Case Reports in Medicine, 2021 Amyloidosis is an underappreciated medical condition with symptoms camouflaging as common medical comorbidities leading to its underdiagnosis due to its systemic involvement.
Constantine N. Logothetis +2 more
doaj +2 more sources
Management of transthyretin amyloidosis [PDF]
Swiss medical weekly, 2021 Transthyretin amyloidosis (ATTR amyloidosis) is a disease caused by deposition of transthyretin fibrils in organs and tissues, which causes their dysfunction. The clinical heterogeneity of ATTR amyloidosis and the variable presentation of symptoms at early disease stages, historically meant treatment delays. Diagnostic tools and therapy options of ATTR
Condoluci, Adalgisa +43 more
openaire +5 more sources
Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis [PDF]
Drug Design, Development and Therapy, 2019 Veena Mathew,1 Annabel K Wang1,2 1Department of Neurology, UCI ALS and Neuromuscular Center, University of California, Irvine, Orange, CA, USA; 2Neurology Section, Tibor Rubin VA Medical Center, Long Beach, CA, USA Abstract: Hereditary transthyretin ...
Mathew V, Wang AK
doaj +3 more sources
Utility of Genetic Testing in Patients with Transthyretin Amyloid Cardiomyopathy: A Brief Review
Biomedicines, 2023 Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly diagnosed condition. Although wild-type transthyretin amyloidosis (ATTRwt) is the most common ATTR-CM, hereditary transthyretin amyloidosis (ATTRv) may also occur.
Ana-Maria Merino-Merino +4 more
doaj +1 more source
International Journal of Molecular Sciences, 2023 Transthyretin amyloidosis (ATTR) is a progressive and systemic disease caused by the misfolding and amyloid aggregation of transthyretin (TTR). Stabilizing the TTR tetramers and disrupting the formed TTR aggregation are treated as a promising strategy for the treatment of ATTR.
Huizhen Zou, Shuangyan Zhou
openaire +2 more sources
Indonesian Biomedical Journal, 2022 BACKGROUND: Transthyretin protein experiences misfolding and aggregation in preeclampsia due to placental ischemia and inflammation. Placental endothelial damage occurring in preeclampsia stimulates the production of larger young platelets in the bone ...
Asri Ragil Kemuning +4 more
doaj +1 more source
Identification of Transthyretin Tetramer Kinetic Stabilizers That Are Capable of Inhibiting the Retinol-Dependent Retinol Binding Protein 4-Transthyretin Interaction [PDF]
, 2021 Dissociation of transthyretin (TTR) tetramers may lead to misfolding and aggregation of pro-amyloidogenic monomers, which underlies TTR amyloidosis (ATTR) pathophysiology.
Arun, Raja +7 more
core +1 more source